Cargando…

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes

Better biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed. We explored the predictive value of early response evaluation using Fluor-18-deoxyglucose positron emission tomography and pre- and on-treatment flowcytometric T-cell p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borm, Frank J., Smit, Jasper, Bakker, Joyce, Wondergem, Maurits, Smit, Egbert F., de Langen, Adrianus J., de Gruijl, Tanja D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142313/ https://www.ncbi.nlm.nih.gov/pubmed/37123045 http://dx.doi.org/10.1080/2162402X.2023.2204745

Ejemplares similares

High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes
por: van de Ven, Rieneke, et al.
Publicado: (2017)

Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy
por: Borm, Frank J., et al.
Publicado: (2021)

(18)F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer
por: Borm, Frank Johannes, et al.
Publicado: (2020)

Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy
por: Niemeijer, Anna-Larissa Nadia, et al.
Publicado: (2020)

Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
por: Kolinger, Guilherme D., et al.
Publicado: (2019)

Unlocking the therapeutic potential of primary tumor-draining lymph nodes
por: Rotman, Jossie, et al.
Publicado: (2019)

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
por: de Langen, Adrianus J., et al.
Publicado: (2018)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Effects of Tracer Uptake Time in Non–Small Cell Lung Cancer (18)F-FDG PET Radiomics
por: Kolinger, Guilherme D., et al.
Publicado: (2022)

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation
por: van Velden, Floris H. P., et al.
Publicado: (2016)

Detection of Circulating Tumor Cells Using the Attune NxT
por: Gruijs, Mandy, et al.
Publicado: (2022)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Hondelink, Liesbeth M., et al.
Publicado: (2021)

Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth
por: Heeren, Anne Marijne, et al.
Publicado: (2021)

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
por: Lin, Lishi, et al.
Publicado: (2021)

What does radiomics do in PD‐L1 blockade therapy of NSCLC patients?
por: Cui, Ruichen, et al.
Publicado: (2022)

Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome
por: Ma, Shaokang, et al.
Publicado: (2019)

Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade
por: Kanda, Yasuhiro, et al.
Publicado: (2021)

Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
por: Wang, Shuhang, et al.
Publicado: (2022)

Mechanisms of Tumor-Induced Lymphovascular Niche Formation in Draining Lymph Nodes
por: Commerford, Catharina D., et al.
Publicado: (2018)

slanDCs in carcinoma-draining lymph nodes
por: Vermi, William, et al.
Publicado: (2014)

PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients
por: Wu, X, et al.
Publicado: (2014)

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC
por: Kaira, Kyoichi, et al.
Publicado: (2022)

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients
por: Zom, Gijs G., et al.
Publicado: (2016)

Dendritic Cell Migration to Skin-Draining Lymph Nodes Is Controlled by Dermatan Sulfate and Determines Adaptive Immunity Magnitude
por: Nadafi, Reza, et al.
Publicado: (2018)

Impact of fasting on (18)F-fluorocholine gastrointestinal uptake and detection of lymph node metastases in patients with prostate cancer
por: Wondergem, Maurits, et al.
Publicado: (2016)

Comment on Cho et al.: Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction
por: van der Veldt, Astrid A. M., et al.
Publicado: (2011)

Tumor-draining lymph node-derived tumor-specific memory CD8(+) T cells: a key player in PD-1/PD-L1 immunotherapy
por: Yin, Enzhi, et al.
Publicado: (2023)

Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells
por: Piersiala, Krzysztof, et al.
Publicado: (2022)

STUDIES OF THE CELLS IN THE AFFERENT AND EFFERENT LYMPH OF LYMPH NODES DRAINING THE SITE OF SKIN HOMOGRAFTS
por: Hall, J. G.
Publicado: (1967)

Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials
por: Man, Johnathan, et al.
Publicado: (2021)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
por: Della Corte, Carminia Maria, et al.
Publicado: (2019)

Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights
por: Fransen, Marieke F., et al.
Publicado: (2021)

Implications of False Negative and False Positive Diagnosis in Lymph Node Staging of NSCLC by Means of (18)F-FDG PET/CT
por: Li, Shaolei, et al.
Publicado: (2013)

ADC Values of Cytologically Benign and Cytologically Malignant 18 F-FDG PET-Positive Lymph Nodes of Head and Neck Squamous Cell Carcinoma
por: de Koekkoek-Doll, Petra K., et al.
Publicado: (2022)

Tumor mutational load, CD8(+) T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Hematogenous muscular metastasis of NSCLC in FDG-PET/CT
por: Satoh, Hiroaki, et al.
Publicado: (2015)

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
por: Niemeijer, A. N., et al.
Publicado: (2018)

Tumor-Draining Lymph Secretome En Route to the Regional Lymph Node in Breast Cancer Metastasis
por: Mohammed, Sulma I, et al.
Publicado: (2020)

PD-L1(+) lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients
por: Raniszewska, A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9r21b4g8g07niq05uhtau56j0d